MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression

Current Medicinal Chemistry

Volumn 21, Issue 17, 2014, Pages 2012-2022

  Shih, Chun Ming ^a,b   Chen, Yung Hsiang ^c   Lin, Yi Wen ^b   Tsao, Nai Wen ^b   Wu, Shinn Chih ^d   Kao, Yung Ta ^b   Chiang, Kuang Hsing ^b   Li, Chi Yuan ^e   Chang, Nen Chung ^a,b   Lin, Cheng Yen ^f   Huang, Chun Yao ^a,b   Lin, Feng Yen ^a,b  

^a Department of Internal Medicine School of Medicine College of Medicine ^*  (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f HUNGKUANG UNIVERSITY   (Taiwan)

Author keywords

Dipeptidyl peptidase 4; Endothelial nitric oxide synthase; Endothelial progenitor cells; Stromal cell derived factor 1

Indexed keywords

CELL SURFACE MARKER; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCAGON LIKE PEPTIDE 1; MK 0626; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; MK0626; TRIAZOLE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CAPILLARY DENSITY; CELL HOMING; CELL MOTILITY; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DRUG SAFETY; ENDOTHELIAL PROGENITOR CELL; FLOW CYTOMETRY; IN VIVO STUDY; LASER DOPPLER FLOWMETRY; LIMB BLOOD FLOW; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; THIGH; ANIMAL; C57BL MOUSE; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; ISCHEMIA; LIMB; METABOLISM; PATHOLOGY; VASCULARIZATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CHEMOKINE CXCL12; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIAL PROGENITOR CELLS; EXTREMITIES; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; TRIAZOLES;

EID: 84899872989     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660273     Document Type: Article

References (40)

1. Drucker, D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care, 2007, 30, 1335-1343.
2. Weber, A.E. Dipeptidyl peptidase iv inhibitors for the treatment of diabetes. J. Med. Chem., 2004, 47, 4135-4141.
3. Tranah, G.J.; Giovannucci, E.; Ma, J.; Fuchs, C.; Hankinson, S.E.; Hunter, D.J. Xrcc2 and xrcc3 polymorphisms are not associated with risk of colorectal adenoma. Cancer Epidemiol. Biomarkers Prev., 2004, 13, 1090-1091.
4. Mahnken, A.H.; Wildberger, J.E.; Adam, G.; Stanzel, S.; Schmitz-Rode, T.; Gunther, R.W.; Buecker, A. Is there a need for contrastenhanced t1-weighted mri of the spine after inconspicuous short tau inversion recovery imaging? Eur. Radiol., 2005, 15, 1387-1392.
5. Gautier, J.F.; Fetita, S.; Sobngwi, E.; Salaun-Martin, C. Biological actions of the incretins gip and glp-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab., 2005, 31, 233-242.
6. Mentlein, R.; Gallwitz, B.; Schmidt, W.E. Dipeptidyl-peptidase iv hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem., 1993, 214, 829-835.
7. Mannucci, E.; Pala, L.; Ciani, S.; Bardini, G.; Pezzatini, A.; Sposato, I.; Cremasco, F.; Ognibene, A.; Rotella, C.M. Hyperglycaemia increases dipeptidyl peptidase iv activity in diabetes mellitus. Diabetologia, 2005, 48, 1168-1172.
8. Ryskjaer, J.; Deacon, C.F.; Carr, R.D.; Krarup, T.; Madsbad, S.; Holst, J.; Vilsboll, T. Plasma dipeptidyl peptidase-iv activity in patients with type-2 diabetes mellitus correlates positively with hbalc levels, but is not acutely affected by food intake. Eur. J. Endocrinol., 2006, 155, 485-493.
9. Fadini, G.P.; Boscaro, E.; Albiero, M.; Menegazzo, L.; Frison, V.; de Kreutzenberg, S.; Agostini, C.; Tiengo, A.; Avogaro, A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: Possible role of stromal-derived factor-1alpha. Diabetes Care, 2010, 33, 1607-1609.
10. Oeseburg, H.; de Boer, R.A.; Buikema, H.; van der Harst, P.; van Gilst, W.H.; Sillje, H.H. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase a. Arterioscler. Thromb. Vasc. Biol., 2010, 30, 1407-1414.
11. Busso, N.; Wagtmann, N.; Herling, C.; Chobaz-Peclat, V.; Bischof-Delaloye, A.; So, A.; Grouzmann, E. Circulating cd26 is negatively associated with inflammation in human and experimental arthritis. Am. J. Pathol., 2005, 166, 433-442.
12. Christopherson, K.W., 2nd; Hangoc, G.; Mantel, C.R.; Broxmeyer, H.E. Modulation of hematopoietic stem cell homing and engraftment by cd26. Science, 2004, 305, 1000-1003.
13. Huang, C.Y.; Shih, C.M.; Tsao, N.W.; Lin, Y.W.; Huang, P.H.; Wu, S.C.; Lee, A.W.; Kao, Y.T.; Chang, N.C.; Nakagami, H.; Morishita, R.; Ou, K.L.; Hou, W.C.; Lin, C.Y.; Shyu, K.G.; Lin, F.Y. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells. Br. J. Pharmacol., 2012, 167(7), 1506-1519.
14. Nystrom, T.; Gutniak, M.K.; Zhang, Q.; Zhang, F.; Holst, J.J.; Ahren, B.; Sjoholm, A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab., 2004, 287, E1209-E1215.
15. Edmondson, S.D.; Mastracchio, A.; Mathvink, R.J.; He, J.; Harper, B.; Park, Y.J.; Beconi, M.; Di Salvo, J.; Eiermann, G.J.; He, H.; Leiting, B.; Leone, J.F.; Levorse, D.A.; Lyons, K.; Patel, R.A.; Patel, S.B.; Petrov, A.; Scapin, G.; Shang, J.; Roy, R.S.; Smith, A.; Wu, J.K.; Xu, S.; Zhu, B.; Thornberry, N.A.; Weber, A.E. (2s,3s)-3-amino-4-(3,3-difluoropyrrolidin-1-yl)-n, n-dimethyl-4-oxo-2-(4-[1,2,4]tr iazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: A selective alpha-amino amide dipeptidyl peptidase iv inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 2006, 49, 3614-3627.
16. Huang, P.H.; Tsai, H.Y.; Wang, C.H.; Chen, Y.H.; Chen, J.S.; Lin, F.Y.; Lin, C.P.; Wu, T.C.; Sata, M.; Chen, J.W.; Lin, S.J. Moderate intake of red wine improves ischemia-induced neovascularization in diabetic mice-roles of endothelial progenitor cells and nitric oxide. Atherosclerosis, 2010, 212, 426-435.
17. Yoder, M.C. No role in epc function. Blood, 2005, 105, 1846-1847.
18. Ban, K.; Noyan-Ashraf, M.H.; Hoefer, J.; Bolz, S.S.; Drucker, D.J.; Husain, M. Cardioprotective and vasodilatory actions of glucagonlike peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation, 2008, 117, 2340-2350.
19. Marfella, R.; Luongo, C.; Coppola, A.; Luongo, M.; Capodanno, P.; Ruggiero, R.; Mascolo, L.; Ambrosino, I.; Sardu, C.; Boccardi, V.; Lettieri, B.; Paolisso, G. Use of a non-specific immunomodulation therapy as a therapeutic vasculogenesis strategy in nooption critical limb ischemia patients. Atherosclerosis, 2010, 208, 473-479.
20. Lawall, H.; Bramlage, P.; Amann, B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J. Vasc. Surg., 2011, 53, 445-453.
21. Fadini, G.P.; Losordo, D.; Dimmeler, S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ. Res., 2012, 110, 624-637.
22. Kim, K.A.; Shin, Y.J.; Kim, J.H.; Lee, H.; Noh, S.Y.; Jang, S.H.; Bae, O.N. Dysfunction of endothelial progenitor cells under diabetic conditions and its underlying mechanisms. Arch. Pharm. Res., 2012, 35, 223-234.
23. Tousoulis, D.; Andreou, I.; Antoniades, C.; Tentolouris, C.; Stefanadis, C. Role of inflammation and oxidative stress in endothelial progenitor cell function and mobilization: Therapeutic implications for cardiovascular diseases. Atherosclerosis, 2008, 201, 236-247.
24. Jarajapu, Y.P.; Grant, M.B. The promise of cell-based therapies for diabetic complications: Challenges and solutions. Circ. Res., 2010, 106, 854-869.
25. Ravassa, S.; Zudaire, A.; Diez, J. Glp-1 and cardioprotection: From bench to bedside. Cardiovasc. Res., 2012, 94, 316-323.
26. Mannucci, E.; Dicembrini, I. Incretin-based therapies and cardiovascular risk. Curr. Med. Res. Opin., 2012, 28, 715-721.
27. Ding, L.; Zhang, J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol. Sin., 2012, 33, 75-81.
28. Sangle, G.V.; Lauffer, L.M.; Grieco, A.; Trivedi, S.; Iakoubov, R.; Brubaker, P.L. Novel biological action of the dipeptidylpeptidaseiv inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. Endocrinology, 2012, 153, 564-573.
29. Penn, M.S.; Pastore, J.; Miller, T.; Aras, R. Sdf-1 in myocardial repair. Gene Ther., 2012, 19, 583-587.
30. Sharma, M.; Afrin, F.; Satija, N.; Tripathi, R.P.; Gangenahalli, G.U. Stromal-derived factor-1/cxcr4 signaling: Indispensable role in homing and engraftment of hematopoietic stem cells in bone marrow. Stem Cells Dev., 2011, 20, 933-946.
31. Peled, A.; Wald, O.; Burger, J. Development of novel cxcr4-based therapeutics. Expert Opin. Investig. Drugs, 2012, 21, 341-353.
32. Mallat, Z. Pi3kgamma helps an sdf seeking home... For epcs. Circ. Res., 2008, 102, 871-872.
33. Deng, X.; Szabo, S.; Chen, L.; Paunovic, B.; Khomenko, T.; Tolstanova, G.; Tarnawski, A.S.; Jones, M.K.; Sandor, Z. New cell therapy using bone marrow-derived stem cells/endothelial progenitor cells to accelerate neovascularization in healing of experimental ulcerative colitis. Curr. Pharm. Des., 2011, 17, 1643-1651.
34. Yamaguchi, J.; Kusano, K.F.; Masuo, O.; Kawamoto, A.; Silver, M.; Murasawa, S.; Bosch-Marce, M.; Masuda, H.; Losordo, D.W.; Isner, J.M.; Asahara, T. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation, 2003, 107, 1322-1328.
35. Gallagher, K.A.; Liu, Z.J.; Xiao, M.; Chen, H.; Goldstein, L.J.; Buerk, D.G.; Nedeau, A.; Thom, S.R.; Velazquez, O.C. Diabetic impairments in no-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and sdf-1 alpha. J. Clin. Invest., 2007, 117, 1249-1259.
36. Ceradini, D.J.; Kulkarni, A.R.; Callaghan, M.J.; Tepper, O.M.; Bastidas, N.; Kleinman, M.E.; Capla, J.M.; Galiano, R.D.; Levine, J.P.; Gurtner, G.C. Progenitor cell trafficking is regulated by hypoxic gradients through hif-1 induction of sdf-1. Nat. Med., 2004, 10, 858-864.
37. Birnbaum, Y.; Castillo, A.C.; Qian, J.; Ling, S.; Ye, H.; Perez-Polo, J.R.; Bajaj, M.; Ye, Y. Phosphodiesterase iii inhibition increases camp levels and augments the infarct size limiting effect of a dpp-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovascular drugs and therapy /sponsored by the International Society of Cardiovascular Pharmacotherapy. 2012, 26, 445-456.
38. Timmermans, F.; Plum, J.; Yoder, M.C.; Ingram, D.A.; Vandekerckhove, B.; Case, J. Endothelial progenitor cells: Identity defined? J. Cell. Mol. Med., 2009, 13, 87-102.
39. Huang, P.H.; Lin, C.P.; Wang, C.H.; Chiang, C.H.; Tsai, H.Y.; Chen, J.S.; Lin, F.Y.; Leu, H.B.; Wu, T.C.; Chen, J.W.; Lin, S.J. Niacin improves ischemia-induced neovascularization in diabetic mice by enhancement of endothelial progenitor cell functions independent of changes in plasma lipids. Angiogenesis, 2012, 15, 377-389.
40. Liu, Y.; Hu, Y.; Liu, T. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects. Curr. Med. Chem., 2012, 19(23), 3982-3999.